Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, Thursday announced that it has appointed Hubert Chen, as its Chief Medical Officer.
Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory strategy, and product approvals across multiple therapeutic areas.
Prior to joining Viking, Hubert Chen served as the chief research and development officer at Loyal Animal Health. Previously, he was president and chief scientific officer at Forte Biosciences.
In pre-market activity, VKTX shares were trading at $27.84, down 0.32% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.